Peptide-based supramolecular hydrogels are rapidly advancing as targeted drug delivery platforms, offering sustained release and reduced side effects compared to systemic drug administration.
Targeted vs. systemic deliveryPeptide hydrogels enable localized drug release at treatment sites, potentially reducing doses and avoiding off-target toxicity from conventional systemic administration
What the researchers found
The review highlights that peptide-based supramolecular hydrogels have made significant advances in drug delivery through several key developments: improved peptide self-assembly techniques that create more stable gel structures, functionalization strategies that enable targeted delivery, bioadhesive properties that keep gels in place at treatment sites, and enhanced drug release profiles that can be tuned for sustained or triggered release.
Particularly notable progress has been made in anticancer drug loading and release, where different hydrogel matrix designs allow controlled delivery of chemotherapy agents directly to tumor sites, potentially reducing the systemic toxicity associated with conventional chemotherapy.
Why it matters
Systemic drug delivery — where a drug circulates throughout the entire body — causes side effects from off-target binding. Peptide hydrogels enable localized, sustained drug release at the treatment site, which could transform how diseases like cancer are treated by delivering effective doses where they're needed while minimizing toxicity elsewhere.
How the study worked
This is a comprehensive literature review covering discoveries in peptide-based supramolecular hydrogels for drug delivery reported primarily between 2018 and 2022. The authors survey advances in self-assembly, mechanical properties, functionalization, bioadhesion, drug release profiles, and anticancer drug delivery applications.
What this study cannot tell us
As a review, this paper synthesizes existing literature rather than presenting new experimental data. Many of the advances described are at the preclinical stage, and the translation of peptide hydrogels from laboratory to clinical use faces challenges including scalability, regulatory approval, and long-term stability in biological environments.
How to read the evidence
This is a narrative review summarizing recent advances in peptide hydrogel drug delivery. While it covers a wide range of studies, most evidence comes from in vitro and preclinical experiments rather than human clinical trials.
When this study was published
Published in 2022 covering literature through that year. This is a relatively recent review, though the field continues to advance rapidly and newer developments may have occurred since publication.
The bigger picture
Peptide hydrogels sit at the intersection of peptide science and materials engineering, representing a growing field where peptides serve not as the therapeutic agent but as the delivery vehicle. As personalized medicine advances, these tunable, biocompatible gel systems could become standard platforms for delivering a wide range of therapeutics — from small-molecule drugs to biologics — with precision and reduced side effects.
Questions still open
- Which peptide hydrogel formulations are closest to clinical trials for cancer drug delivery?
- Can peptide hydrogels be designed to respond to specific biological signals for truly 'smart' drug release?
- How do the costs and manufacturing complexity of peptide hydrogels compare to existing drug delivery systems?
Common questions
What are peptide hydrogels and how do they deliver drugs?
Why are peptide hydrogels particularly promising for cancer treatment?
Read the original research
Peptide-Based Supramolecular Hydrogels as Drug Delivery Agents: Recent Advances.
Gels (Basel, Switzerland), 8(11)
Citation
Oliveira, Carlos B P; Gomes, Valéria; Ferreira, Paula M T; Martins, José A; Jervis, Peter J. (2022). Peptide-Based Supramolecular Hydrogels as Drug Delivery Agents: Recent Advances.. Gels (Basel, Switzerland), 8(11). https://doi.org/10.3390/gels8110706